DGAP-News: Cytos Biotechnology Ltd and Intercell AG close the sale of the platform technology
(firmenpresse) - Cytos Biotechnology AG / Disposal
08.06.2010 07:15
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Schlieren (Zurich), Switzerland, June 8, 2010 - Cytos Biotechnology Ltd
(SIX:CYTN) announced today that the sale of the platform technology for the
identification of monoclonal antibodies which was announced on May 6, 2010
has closed yesterday. As per agreed terms, the first installment of EUR 10
million of the purchase price has been paid yesterday. The second
installment of EUR 5 million is unconditional and is due on January 31,
2011.
About Cytos Biotechnology
Cytos Biotechnology Ltd is a public Swiss biotechnology company that
specializes in the discovery, development and commercialization of a new
class of biopharmaceutical products - the Immunodrugs(TM). Immunodrugs(TM)
are intended for use in the treatment and prevention of common chronic
diseases, which afflict millions of people worldwide. Immunodrugs(TM) are
designed to instruct the patient's immune system to produce desired
therapeutic antibody or T cell responses that modulate chronic disease
processes. Taking advantage of the high flexibility of its Immunodrug(TM)
platform, Cytos Biotechnology has built a diversified pipeline of
Immunodrug(TM) candidates in various disease areas, of which six are
currently in clinical development. The Immunodrug(TM) candidates are
developed both in-house and together with Novartis, Pfizer and Pfizer
Animal Health. Founded in 1995 as a spinoff from the Swiss Federal
Institute of Technology (ETH) in Zurich, the Company is located in
Schlieren (Zurich). Currently, the Company has 80 full-time employees.
Cytos Biotechnology Ltd is listed on the SIX Swiss Exchange (SIX:CYTN).
About Intercell AG
Intercell AG is an innovative biotechnology company that develops novel
vaccines for the prevention and treatment of infectious diseases with
substantial unmet medical needs. Intercell's vaccine to prevent Japanese
Encephalitis is the Company's first product on the market. The Company's
technology platforms include an antigen-discovery system, adjuvants and a
novel patch-based delivery system (Vaccine Patch, Vaccine Enhancement
Patch). Based on these technologies, Intercell has strategic partnerships
with a number of global pharmaceutical companies, including GSK, Novartis,
Merck&Co., Inc., sanofi-aventis, and Pfizer (formerly Wyeth). The
Company's pipeline of investigational products includes a Travelers'
Diarrhea Vaccine Patch (Phase III), a Pseudomonas vaccine candidate (Phase
II), a vaccine to prevent Pandemic Influenza combining our Vaccine
Enhancement Patch with an injected vaccine (Phase II), a vaccine program
for S. aureus, which is being developed with Merck&Co., Inc. (Phase
II/III), as well as a vaccine candidate for Pneumococcus (Phase I). In
addition, further products focused on infectious diseases are in
pre-clinical development. Intercell is listed on the Vienna stock exchange
under the symbol 'ICLL' (U.S. level one ADR symbol 'INRLY').
This foregoing press release may contain forward-looking statements that
include words or phrases such as 'are expected to', 'are intended for',
'are designed to' or other similar expressions. These forward-lookingstatements are subject to a variety of significant uncertainties, including
scientific, business, economic and financial factors, and therefore actual
results may differ significantly from those presented. There can be no
assurance that any further therapeutic entities will enter clinical trials,
that clinical trial results will be predictive for future results, that
therapeutic entities will be the subject of filings for regulatory
approval, that any drug candidates will receive marketing approval from the
U.S. Food and Drug Administration or equivalent regulatory authorities, or
that drugs will be marketed successfully. Against the background of these
uncertainties readers should not rely on forward-looking statements. The
company assumes no responsibility to update forward-looking statements or
adapt them to future events or developments. This document does not
constitute an offer or invitation to subscribe or purchase any securities
of Cytos Biotechnology Ltd.
Wolfgang A. Renner, PhD
Chief Executive Officer
Cytos Biotechnology Ltd
Phone: +41 44 733 47 03
Fax: +41 44 733 47 04
e-Mail: wolfgang.renner(at)cytos.com
Website: www.cytos.com
08.06.2010 07:15 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv atwww.dgap-medientreff.deandwww.dgap.de---------------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Schweiz
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info(at)cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Freiverkehr in Berlin, München, Stuttgart; Open
Market in Frankfurt; Foreign Exchange(s) SIX
End of News DGAP News-Service
---------------------------------------------------------------------------
Datum: 08.06.2010 - 07:15 Uhr
Sprache: Deutsch
News-ID 22058
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 249 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Cytos Biotechnology Ltd and Intercell AG close the sale of the platform technology"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytos Biotechnology AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
